Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
A legfontosabb adatok
- Ki végzi
- Memorial Sloan Kettering Cancer Center
- Hol
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York és Rockville Centre (Egyesült Államok)Mind a 7 helyszín megnézéseMég 1 másik országban, 1 helyszínen
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 259 fő, tervezett
- Kezdés
- 2026. jan. 30.
- Várható befejezés
- 2030. jan. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- MSK-ACCESS
- ctDNA/VTE Risk Score:
- A regiszteradat frissítve
- 2026. november 9.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 with a history of cancer-associated VTE (objectively confirmed symptomatic or incidental/unsuspected proximal lower-limb DVT, symptomatic pulmonary embolism [PE] or incidental PE in a segmental or more proximal pulmonary artery) and completion of between 3 and 12 months of anticoagulation with enoxaparin, dalteparin,rivaroxaban, or apixaban without current VTE-related symptoms (imaging to confirm resolution not required); Diagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins; Diagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries
- Diagnosis of one of the following solid tumors in either advanced (i.e. unresectable) stage or receiving systemic anticancer treatment within six weeks of enrollment (maintenance therapy included):; breast cancer regardless of cytotoxic-chemotherapy status; hepatobiliary cancer regardless of cytotoxic-chemotherapy status; prostate cancer regardless of cytotoxic-chemotherapy status; non-small cell lung cancer with cytotoxic-chemotherapy received within 30 days; pancreatic cancer with cytotoxic-chemotherapy received within 30 days; bladder cancer with cytotoxic-chemotherapy received within 30 days
- Signed and dated informed consent by study participant/Legally Authorized Representative (LAR)
Ki nem vehet részt
- Contraindication to discontinuation of anticoagulation (examples include but not limited to: known antiphospholipid syndrome or factor V leiden, active arterial thrombus, catheter-associated thrombus, on anticoagulation for atrial fibrillation or other non-oncologic reasons)
- Diagnosis of an active hematologic malignancy
- History of major bleeding in the last six months (major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; bleeding that necessitates acute surgical intervention; bleeding causing a fall in hemoglobin levels of 1.24 mmol/L (2 g/dL or greater) or more; or bleeding leading to a transfusion of 2 U or more of whole blood or red cells)
- Contraindication to ongoing anticoagulation
- Known diagnosis of disseminated intravascular coagulation (DIC)
- Suspicion for tumor thrombus on the imaging leading to original diagnosis of VTE
- Enrolled in hospice care
- Currently has inferior vena cava (IVC) filter
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 1 helyszínen
- Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)Basking Ridge, Egyesült ÁllamokContact: Justin Jee, MD, PhDRésztvevőt keres
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, Egyesült ÁllamokContact: Justin Jee, MD, PhDRésztvevőt keres
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, Egyesült ÁllamokContact: Justin Jee, MD, PhDRésztvevőt keres
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, Egyesült ÁllamokContact: Justin Jee, MD, PhDRésztvevőt keres
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, Egyesült ÁllamokContact: Justin Jee, MD, PhDRésztvevőt keres
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)New York, Egyesült ÁllamokContact: Justin Jee, MD, PhDRésztvevőt keres
- Memorial Sloan Kettering Nassau (All Protocol Activities)Rockville Centre, Egyesült ÁllamokContact: Justin Jee, MD, PhDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
A vizsgálat 2 csoportja
- High risk for recurrent Venous Thromboembolism/VTEA vizsgált kezelés
Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk.
Kezelés: MSK-ACCESS és ctDNA/VTE Risk Score:
- Low-risk for recurrent Venous Thromboembolism/VTEA vizsgált kezelés
Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk.
Kezelés: MSK-ACCESS és ctDNA/VTE Risk Score:
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism
- A regiszteradat frissítve
- 2026. november 9.